Premium
Levofloxacin‐induced rhabdomyolysis in a patient on concurrent atorvastatin: Case report and literature review
Author(s) -
Bouchard Jeannette,
De La Peicolas,
Oleksiuk LouiseMarie
Publication year - 2019
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.13010
Subject(s) - rhabdomyolysis , atorvastatin , levofloxacin , medicine , pharmacology , antibiotics , chemistry , biochemistry
Abstract What is known and objective The combination of HMG‐CoA reductase inhibitors (statins) and fluoroquinolones generally is not considered a significant risk factor for rhabdomyolysis. Rhabdomyolysis is a known risk associated with statin therapy but has seldom been described with fluoroquinolone use. We describe a case of acute rhabdomyolysis involving the co‐administration of atorvastatin and levofloxacin. Case description A 65‐year‐old white male presented with clinical and laboratory evidence of rhabdomyolysis after approximately 19 days of levofloxacin therapy for treatment of a prosthetic joint infection. His symptoms resolved after discontinuation of levofloxacin and atorvastatin therapy and did not recur following reintroduction of atorvastatin therapy. What is new and conclusion Delayed‐onset rhabdomyolysis may occur in patients receiving levofloxacin. Weekly complete metabolic panels along with patient education about symptoms of rhabdomyolysis should be considered, particularly in patients on concurrent medications known to cause rhabdomyolysis.